Navigation Links
Arena Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference
Date:12/8/2011

SAN DIEGO, Dec. 8, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present at the Oppenheimer 22nd Annual Healthcare Conference on Wednesday, December 14, 2011, at 10:15 a.m. Eastern Time (7:15 a.m. Pacific Time) at the Waldorf=Astoria in New York City. Jack Lief, Arena's President and Chief Executive Officer, is scheduled to provide a corporate overview.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate is intended for weight management.

Arena Pharmaceuticals® and Arena® are registered service marks of the company.

Forward-Looking Statements Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the therapeutic indication of Arena's most advanced drug candidate and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the timing of regulatory review and approval is uncertain; regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; the risk that data and other information related to Arena's research and development programs may not meet safety or efficacy requirements or otherwise be sufficient for regulatory approval; Arena's response to the complete response letter for the lorcaserin new drug application or submission of a marketing authorization application for regulatory approval of lorcaserin may not be submitted when anticipated, if at all; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; Arena's ability to obtain adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Arena Pharmaceuticals, Inc.Robert E. Hoffman, Vice President, Finance and Chief Financial Officer

858.453.7200 Investor Contact: Russo Partners, LLC

Media Contact: Russo Partners, LLCCindy McGee, Vice President

David Schull, President cindy.mcgee@russopartnersllc.com

david.schull@russopartnersllc.com619.213.6995

858.717.2310 

 

 


'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arena Pharmaceuticals to Present at the Piper Jaffray 23rd Annual Health Care Conference
2. Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results
3. Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
4. Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer
5. Arena Pharmaceuticals Announces Second Quarter 2011 Financial Results
6. Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study
7. Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9
9. Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
10. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
11. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... India , May 25, 2016 ... Animation Market by Type (3D, 2D, 4D), by Therapeutic ... Education), by End User (Medical Device Manufacturers, Hospitals/ Clinics) ... studies the global Medical Animation Market for the forecast ... to reach USD 301.3 Million by 2021 from USD ...
(Date:5/25/2016)... 2016  According to Kalorama Information, the world ... 2015.  Though these are challenging times in the ... success for companies that remain optimistic and seek ... growth prospects medical device companies spend a higher ... (R&D) than do companies in other industries.  Also, ...
(Date:5/25/2016)... , May 25, 2016 Digital ... issuance to it by the US Patent and ... company,s technology includes proprietary processes for electronic opt-­in ... health and wellness programs, HIPAA compliance and otherwise. ... "Our technology allows ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... Leadership of ... today announced the organization has earned its ISO 13485 certification, indicating the company’s ... with all rules and policies associated with ISO quality standard 13485. , ...
(Date:5/26/2016)... ... May 26, 2016 , ... The Lung Institute has partnered ... cessation class starting June 6 at their clinic in downtown Tampa. The class is ... the Lung Institute has created a free downloadable 4 Week Smoking Cessation Guide ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... offering campers a multitude of activities from daily practices, arts & crafts, discussions, ... Camp Directors Amber East-D’Anna and Christy Evans have combined backgrounds in kids’ yoga, ...
(Date:5/26/2016)... ... May 26, 2016 , ... The MIAMI Institute for Age ... speaker Dr. Adonis Maiquez MD, ABAARM. Dr. Adonis , Wellness Physician of the ... a member of the Institute for Functional Medicine. , He also heads up FITTLab, ...
(Date:5/26/2016)... ... 2016 , ... Power Systems, a leading developer and supplier ... Course in Stoughton, Massachusetts. The course was led by Power Systems’ Education Coordinator, ... interactive course to qualify participants as certified PowerWave trainers. , PowerWave is ...
Breaking Medicine News(10 mins):